News

Combo olaparib/cediranib slaps down recurrent ovarian cancer

Publish date: July 10, 2014

 

AT THE ASCO ANNUAL MEETING 2014

References

pwendling@frontlinemedcom.com

Pages

Recommended Reading

AUDIO: Challenges, rewards face creators of pediatric oncofertility clinics
MDedge Hematology and Oncology
Cobas HPV test for first-line screening for cervical cancer
MDedge Hematology and Oncology
ASCO: Extend adjuvant endocrine therapy to 10 years
MDedge Hematology and Oncology
VIDEO: Investigational combo stalls progression in recurrent ovarian cancer
MDedge Hematology and Oncology
Immunotherapy shows promise in metastatic cervical cancer
MDedge Hematology and Oncology
VIDEO: Immunotherapy as treatment for cervical cancer
MDedge Hematology and Oncology
VIDEO: Metastatic cervical cancer yields to immunotherapy
MDedge Hematology and Oncology
Cancer survivors have higher medical costs
MDedge Hematology and Oncology
VIDEO: Team approach is best for successful oncofertility clinic
MDedge Hematology and Oncology
Phase III trial results needed before PARP inhibitor approved for ovarian cancer indication
MDedge Hematology and Oncology

Related Articles